**METHODS**

**Study design**
- The ALLEGRO phase 2b/3 trial was an international, randomized, double-blind, placebo-controlled, combined dose-ranging and pivotal study (Figure 1).

**Study population**
- Inclusion criteria included:
  - Age ≥12 years
  - AA with ≥50% scalp hair loss
  - Patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study

**Outcome measures**
- The proportions of ritilecitinib-treated patients with clinical response at Week 24, who sustained this response through Week 48, were assessed in this post hoc analysis.
- For each endpoint (SALT score ≤20, SALT score ≤10, EBA, or ELA score) sustained response required:
  - Response at Week 24 and Week 48, and
  - No loss of response at any time point (Weeks 28, 34, or 40)
- Patients with missing data at Week 24 or Week 48 were excluded from this analysis

**Statistical analysis**
- Descriptive analyses were used to evaluate the proportion of ritilecitinib-treated patients with a clinical response at Week 24, who sustained this response through Week 48
- 95% CIs were calculated based on normal approximation

**RESULTS**

**Table 1. Baseline characteristics of patients with SALT score ≤20 response at Week 24**

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>SALT score ≤20 (n=52)</th>
<th>SALT score ≤10 (n=52)</th>
<th>EBA (n=48)</th>
<th>ELA (n=48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD)</td>
<td>35.7 (9.4)</td>
<td>36.8 (9.4)</td>
<td>36.9 (9.4)</td>
<td>37.0 (9.4)</td>
</tr>
<tr>
<td>Standard deviation</td>
<td>23.5</td>
<td>24.3</td>
<td>24.0</td>
<td>24.2</td>
</tr>
<tr>
<td>Median</td>
<td>37.0</td>
<td>37.5</td>
<td>37.0</td>
<td>37.0</td>
</tr>
<tr>
<td>Range</td>
<td>18-68</td>
<td>19-68</td>
<td>16-58</td>
<td>15-68</td>
</tr>
</tbody>
</table>

**Table 2. Baseline characteristics of patients with SALT score ≤10 response at Week 24**

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>SALT score ≤10 (n=52)</th>
<th>EBA (n=48)</th>
<th>ELA (n=48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD)</td>
<td>35.7 (9.4)</td>
<td>36.9 (9.4)</td>
<td>37.0 (9.4)</td>
</tr>
<tr>
<td>Standard deviation</td>
<td>23.5</td>
<td>24.0</td>
<td>24.2</td>
</tr>
<tr>
<td>Median</td>
<td>37.0</td>
<td>37.0</td>
<td>37.0</td>
</tr>
<tr>
<td>Range</td>
<td>18-68</td>
<td>16-58</td>
<td>15-68</td>
</tr>
</tbody>
</table>

**Table 3. Baseline characteristics of patients with SALT score ≤10 response at Week 24**

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>SALT score ≤10 (n=52)</th>
<th>EBA (n=48)</th>
<th>ELA (n=48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD)</td>
<td>35.7 (9.4)</td>
<td>36.9 (9.4)</td>
<td>37.0 (9.4)</td>
</tr>
<tr>
<td>Standard deviation</td>
<td>23.5</td>
<td>24.0</td>
<td>24.2</td>
</tr>
<tr>
<td>Median</td>
<td>37.0</td>
<td>37.0</td>
<td>37.0</td>
</tr>
<tr>
<td>Range</td>
<td>18-68</td>
<td>16-58</td>
<td>15-68</td>
</tr>
</tbody>
</table>

**Figure 1. ALLEGRO-2b/3 Study Design**

**Figure 2. Sustained response based on SALT score ≤20**

**Figure 3. Sustained response based on EBA score**

**Figure 4. Sustained response based on ELA score**

**Figure 5. Sustained response based on EBA score**

**CONCLUSIONS**

- In this post hoc analysis, sustained hair regrowth response was achieved with continued ritilecitinib treatment through Week 48 in the majority of patients with AA who had a clinical response based on scalp, eyebrow, or eyelash regrowth at Week 24
- Additional trials are required to assess longer-term sustained hair regrowth in patients receiving ritilecitinib, as some patients may need >24 weeks to reach a clinical response